Strong Top-Line Revenue Growth
Revenue grew 16.7% year-over-year to $1.65B in Q1 FY2026 from $1.41B in the prior year period, reflecting robust demand across Edwards' product portfolio, particularly in structural heart therapies.
Edwards Lifesciences Corp 已通过 8-K 新闻稿公布 Q2 2026 业绩，10-Q 提交后将自动生成完整 AI 解读。
上一期分析暂无中文版，相关内容以英文显示。
Second-quarter 2026 net sales increased 13.6% year over year to $1.741 billion, while adjusted diluted EPS was $0.78 versus $0.67 a year earlier.
营收
17.41亿美元
预期 17.51亿美元
不及预期 -0.6%每股收益 (non-GAAP)
0.78美元
预期 0.76美元
超预期 +2.3%业绩指引
For Q3 2026, Edwards projects total sales of $1.63 billion to $1.71 billion and adjusted EPS of $0.71 to $0.77; for full-year 2026, it expects total sales of $6.6 billion to $6.9 billion and adjusted EPS of $2.95 to $3.05.
来源：SEC Form 8-K（Item 2.02），EX-99.1 press release。数字为公司自报，预期值来自 Finnhub 分析师一致预期。这是当日快照——完整 AI 解读（管理层讨论、风险、审计意见）将在 10-Q/10-K 提交后自动生成。
想第一时间拿到完整解读？ 关注 Edwards Lifesciences Corp，完整报告生成后我们会通知你。
摘自 Q1 2026 10-Q 中的管理层讨论：
Revenue grew 16.7% year-over-year to $1.65B in Q1 FY2026 from $1.41B in the prior year period, reflecting robust demand across Edwards' product portfolio, particularly in structural heart therapies.
Operating income rose 21.0% YoY to $477.6M, outpacing revenue growth, with operating margin expanding approximately 100 basis points to 29.0% from 27.9%, indicating improving operational efficiency despite rising SG&A costs.
SG&A expenses increased 12.1% YoY to $522.2M, representing a meaningful cost headwind, though the company managed to expand operating margins by controlling R&D growth to just 3.4% YoY at $263.3M.
Revenue
16.49亿美元
+16.70% 同比
EPS (Diluted)
0.66美元
+8.20% 同比
Gross Margin
78.0%
-0.6 个百分点 同比
Operating Income
4.78亿美元
+20.97% 同比
将 EW 加入关注列表，10-Q 提交后几分钟内即可在邮箱收到 AI 解读。